Beam Therapeutics reports Q2 EPS ($1.11), consensus ($1.13)

Reports Q2 revenue $11.77M, consensus $14.18M. Ended Q2 with $1.0B in cash, cash equivalents and marketable securities, providing an expected operating runway into 2027. “This quarter we’ve made significant progress across our rapidly expanding clinical portfolio, where each program utilizes the power and precision of base editing technology to provide potential best-in-class genetic medicines for patients,” said CEO John Evans. “In our genetic disease franchise, we’re pleased to announce the clearance of our U.S. investigational new drug application for BEAM-301, our first U.S. in vivo regulatory filing. We’re focused on initiating site activation activities for BEAM-301 as well as continuing to enroll our BEAM-302 Phase 1/2 clinical trial in alpha-1 antitrypsin deficiency following study initiation in June. We look forward to reporting the first data from the BEAM-302 trial next year. In addition, enrollment in the BEACON trial of BEAM-101 in sickle cell disease has exceeded expectations, with more than 20 patients enrolled and six dosed, plus additional patients consented and in the screening process. Initial BEAM-101 clinical data have been submitted for presentation at the American Society of Hematology Annual Meeting taking place in December, along with abstracts for the first clinical data for BEAM-201 as well as our first ESCAPE preclinical data in non-human primates.”